Document is current
Any future updates will be listed below
-
Authors
Jaeger, Alex M.
Stopfer, Lauren E. http://orcid.org/0000-0001-6984-3004
Ahn, Ryuhjin http://orcid.org/0000-0001-9788-4401
Sanders, Emma A.
Sandel, Demi A. http://orcid.org/0000-0002-4095-2036
Freed-Pastor, William A. http://orcid.org/0000-0002-7377-2111
Rideout, William M. III
Naranjo, Santiago
Fessenden, Tim
Nguyen, Kim B.
Winter, Peter S.
Kohn, Ryan E.
Westcott, Peter M. K. http://orcid.org/0000-0001-9436-4857
Schenkel, Jason M.
Shanahan, Sean-Luc
Shalek, Alex K. http://orcid.org/0000-0001-5670-8778
Spranger, Stefani http://orcid.org/0000-0003-3257-4546
White, Forest M. http://orcid.org/0000-0002-1545-1651
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
- License Information
-
More Information
Article History
Received: 30 June 2021
Accepted: 6 May 2022
First Online: 15 June 2022
Competing interests
: T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics. T.J. is also President of Break Through Cancer. His laboratory currently receives funding from Johnson & Johnson and The Lustgarten Foundation, and funds from the Lustgarten Foundation supported the research described in this manuscript. S.S. is a co-founder of Danger Bio and serves on the Scientific Advisory Board of Related Sciences/DanderBio, Ankyra Therapeutics, Arcus Biosciences, Takeda and Ribon, and serves as an advisor for Dragonfly Therapeutics and Merck. The S.S. Lab currently receives funding from Leap Therapeutics. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ochre Bio, Third Rock Ventures, Hovione, Relation Therapeutics, FL82, Empress Therapeutics and Dahlia Biosciences. None of these affiliations influenced the work conducted or analysis of data presented in this manuscript.
